FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506228185> ?p ?o ?g. }

• W2506228185 endingPage "117" @default.
• W2506228185 startingPage "101" @default.
• W2506228185 abstract "Although, a number of formulations have been developed for the treatment of IBD yet the developed formulations are having side effects such as high dose, lack of solubility and permeability problems at the site of action. Very few formulations have been developed for the IBD treatment in the form of nanoparticles. Nanoparticles have shown their potential in the recent findings in the treatment of IBD at cellular level. This research work aims to develop nanosuspension of newly introduced drug Rifaximin currently available in the form of tablet for the treatment of IBD. Rifaximin in the form of tablet is given in high dose concentration so to avoid the large dose and to increase the permeability action of drug a nanosuspension is prepared using a well known polymer Eudragit S 100 which is itself a colon targeted polymer and simultaneously improves the site specific delivery of the drug.We thoroughly reviewed and tested the previous work for the development of nanoparticles in the laboratory for the treatment of IBD. A number of research as well as review articles were followed in order to get quality information. For this all the research as well as review work was collected from the quality journals. A simple yet a high result oriented technique nanoprecipitation was used for the development of nanoparticles.A total of 21 research and review papers were studied deeply. Before developing the final formula a number of trials were carried out and from the trials, the formulation which showed better release profile and presence of nanoparticles was then optimized and a total of five formulations were developed. In each of the five formulations the concentration of the polymer and external phase was varied along with the concentration change in P.F. 68 for getting a superior formulation in terms of release, size and entrapment. The least size nanosuspension was subjected to Transmission Electron Microscopy for confirmation of nanoparticles and to check the morphological characters of the prepared nanoparticles and size of the nanoparticles was in the range of 19nm to 25nm. The prepared formulation was subjected to stability studies and it was freeze dried.The outcome of this research work confirms the formation of nanoparticles and release profile of the prepared nanosuspension proved its site specificity. The release graphs indicated the release of the drug in colon proving its potential in the treatment of IBD and entrapment study indicates the drug entrapment capacity for delivering the required concentration of drug at the site of action. Moreover, the nanoformulation reduces the dose and the side effects due to its specific targeting at the site of inflammation which makes it a better choice over the tablets." @default.
• W2506228185 created "2016-08-23" @default.
• W2506228185 creator A5057274723 @default.
• W2506228185 creator A5091526312 @default.
• W2506228185 date "2016-12-23" @default.
• W2506228185 modified "2023-09-23" @default.
• W2506228185 title "Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD)" @default.
• W2506228185 cites W1547442408 @default.
• W2506228185 cites W1968848000 @default.
• W2506228185 cites W1980988152 @default.
• W2506228185 cites W1996998905 @default.
• W2506228185 cites W2000252319 @default.
• W2506228185 cites W2026317976 @default.
• W2506228185 cites W2055354698 @default.
• W2506228185 cites W2086725441 @default.
• W2506228185 cites W2110115130 @default.
• W2506228185 cites W2114179392 @default.
• W2506228185 cites W2121469147 @default.
• W2506228185 cites W2125794208 @default.
• W2506228185 cites W2146738959 @default.
• W2506228185 cites W2156661377 @default.
• W2506228185 cites W2157948833 @default.
• W2506228185 cites W2186333035 @default.
• W2506228185 cites W2499255790 @default.
• W2506228185 cites W1582756535 @default.
• W2506228185 doi "https://doi.org/10.2174/1871523015666160720103732" @default.
• W2506228185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27449742" @default.
• W2506228185 hasPublicationYear "2016" @default.
• W2506228185 type Work @default.
• W2506228185 sameAs 2506228185 @default.
• W2506228185 citedByCount "6" @default.
• W2506228185 countsByYear W25062281852017 @default.
• W2506228185 countsByYear W25062281852020 @default.
• W2506228185 countsByYear W25062281852022 @default.
• W2506228185 crossrefType "journal-article" @default.
• W2506228185 hasAuthorship W2506228185A5057274723 @default.
• W2506228185 hasAuthorship W2506228185A5091526312 @default.
• W2506228185 hasConcept C126322002 @default.
• W2506228185 hasConcept C171250308 @default.
• W2506228185 hasConcept C185592680 @default.
• W2506228185 hasConcept C192562407 @default.
• W2506228185 hasConcept C2778260677 @default.
• W2506228185 hasConcept C2778889925 @default.
• W2506228185 hasConcept C2779134260 @default.
• W2506228185 hasConcept C2779820397 @default.
• W2506228185 hasConcept C2780035454 @default.
• W2506228185 hasConcept C501593827 @default.
• W2506228185 hasConcept C55493867 @default.
• W2506228185 hasConcept C71924100 @default.
• W2506228185 hasConcept C77281830 @default.
• W2506228185 hasConcept C98274493 @default.
• W2506228185 hasConceptScore W2506228185C126322002 @default.
• W2506228185 hasConceptScore W2506228185C171250308 @default.
• W2506228185 hasConceptScore W2506228185C185592680 @default.
• W2506228185 hasConceptScore W2506228185C192562407 @default.
• W2506228185 hasConceptScore W2506228185C2778260677 @default.
• W2506228185 hasConceptScore W2506228185C2778889925 @default.
• W2506228185 hasConceptScore W2506228185C2779134260 @default.
• W2506228185 hasConceptScore W2506228185C2779820397 @default.
• W2506228185 hasConceptScore W2506228185C2780035454 @default.
• W2506228185 hasConceptScore W2506228185C501593827 @default.
• W2506228185 hasConceptScore W2506228185C55493867 @default.
• W2506228185 hasConceptScore W2506228185C71924100 @default.
• W2506228185 hasConceptScore W2506228185C77281830 @default.
• W2506228185 hasConceptScore W2506228185C98274493 @default.
• W2506228185 hasIssue "2" @default.
• W2506228185 hasLocation W25062281851 @default.
• W2506228185 hasLocation W25062281852 @default.
• W2506228185 hasOpenAccess W2506228185 @default.
• W2506228185 hasPrimaryLocation W25062281851 @default.
• W2506228185 hasRelatedWork W2093782571 @default.
• W2506228185 hasRelatedWork W2112092103 @default.
• W2506228185 hasRelatedWork W2405839080 @default.
• W2506228185 hasRelatedWork W2460492823 @default.
• W2506228185 hasRelatedWork W2538854790 @default.
• W2506228185 hasRelatedWork W2883365895 @default.
• W2506228185 hasRelatedWork W3091612383 @default.
• W2506228185 hasRelatedWork W3181315649 @default.
• W2506228185 hasRelatedWork W2185339748 @default.
• W2506228185 hasRelatedWork W2783346466 @default.
• W2506228185 hasVolume "15" @default.
• W2506228185 isParatext "false" @default.
• W2506228185 isRetracted "false" @default.
• W2506228185 magId "2506228185" @default.
• W2506228185 workType "article" @default.